Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation.

ABSTRACT:

Aim

The aim of the present study was to characterize the pharmacokinetic profile of corifollitropin alfa and examine the relationships between dose, intrinsic factors [body weight, body mass index (BMI), age and race] and corifollitropin alfa pharmacokinetics.

Methods

Data from five phase II and III clinical trials of corifollitropin alfa were evaluated. All subjects included in the analysis received 60 - 180 μg corifollitropin alfa for controlled ovarian stimulation in a gonadotrophin-releasing hormone antagonist protocol followed by daily recombinant follicle stimulating hormone (rFSH) from day 8 onwards. Serum corifollitropin alfa levels (across the entire range of treatment) and total follicle stimulating hormone immunoreactivity levels (up to the start of rFSH treatment

SUBMITTER: Zandvliet AS 

PROVIDER: S-EPMC4917789 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature